Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients
Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients
复制标题
DOI：
10.1111/j.1468-1293.2010.00907.x
复制
发表时间：
2011-08-01
期刊：
影响因子：
3
通讯作者：
Munoz-Fernandez, M. A.
中科院分区：
文献类型：
--
作者：
Briz, V.;Palladino, C.;Munoz-Fernandez, M. A.
我们评价了依特拉韦林治疗儿童垂直感染HIV-1的有效性、安全性和耐受性。方法对2007年9月1日至2010年2月28日入选的23例儿童和青少年多药耐药患者进行多中心回顾性研究。我们对免疫学、病毒学和临床资料进行纵向分析。结果患者的中位年龄为14.2岁[四分位数范围(IQR)12.5-15.8岁]。基线时，HIV-1RNA中位数为29000(4.5log(10))HIV-1RNA拷贝数/毫升(范围4300-83000拷贝/毫升)，CD4T细胞计数中位数为445个细胞/亩L(范围221-655个/亩L)，CD4%中位数为19.6%(IQR13.0-31.0)。值得注意的是，23名患者中有16名(70%)存在一个或多个依特拉韦林相关耐药突变。在91%的患者中，主干方案包括至少两种完全有效的药物。在以依特拉韦林为基础的治疗后，20名患者(87%)获得了HIV-1RNA
BackgroundWe evaluated the efficacy, safety and tolerability of etravirine in paediatric patients vertically infected with HIV-1.MethodsA multicentre retrospective study of 23 multidrug-resistant paediatric patients (five children and 18 adolescents) enrolled in the study from 1 September 2007 to 28 February 2010 was carried out. We performed a longitudinal analysis of immunological, virological and clinical data.ResultsThe median age of the patients was 14.2 years [interquartile range (IQR) 12.5-15.8 years]. At baseline, the median HIV-1 RNA was 29 000 (4.5 log(10)) HIV-1 RNA copies/mL (range 4300-83 000 copies/mL), the median CD4 T-cell count was 445 cells/mu L (range 221-655 cells/mu L) and the median CD4 percentage was 19.6% (IQR 13.0-31.0). Remarkably, 16 of 23 patients (70%) harboured one or more etravirine-associated resistance mutations. The backbone regimen included at least two fully active drugs in 91% of patients. After etravirine-based therapy, 20 patients (87%) achieved HIV-1 RNA